BLFS vs MNKD: fair value comparison
BioLife Solutions, Inc. and MannKind Corporation · Updated 2026-10-19
BLFS's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. MNKD is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, MNKD currently ranks higher by quality score.
| BLFS | MNKD | |
|---|---|---|
| Verdict | Awaiting full valuation | Awaiting full valuation |
| Last price | $38.61 | $3.04 |
| 12-month range | $18.15–$39.22 | $2.28–$6.21 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #111 of 301 Healthcare | #110 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: BLFS fair value analysis · MNKD fair value analysis